LGDN Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Ligand Pharmaceuticals Inc

Watchlist Manager

Watchlist

Price: 180 EUR -1.64% Market Closed

Market Cap: €3.2B

L	Ligand Pharmaceuticals Inc F:LGDN	US
S	SSE PLC XMUN:SCT	UK
C	Capri Holdings Ltd SWB:MKO	UK
A	Allegheny Technologies Inc F:ATD	US
K	KLA Corp XHAM:KLA	US
K	Koninklijke Philips NV XMUN:PHI1	NL
	APA Group F:PJZ	AU
	Yext Inc NYSE:YEXT	US
T	Tapestry Inc F:COY	US
C	China Citic Bank Corp Ltd SWB:D7C	CN
S	Sanmina Corp F:SAYN	US
A	American International Group Inc XMUN:AINN	US
O	Olam International Ltd F:O5I	SG
A	Akamai Technologies Inc XHAM:AK3	US

Profitability Summary

Ligand Pharmaceuticals Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

95%

Strong 3Y Average Gross Margin

90%

Gross Margin is Increasing

72% > 95%

Healthy Operating Margin

18%

Low 3Y Average Operating Margin

Declining Operating Margin

20% > 18%

Exceptional Net Margin

46%

Sustainable 3Y Average Net Margin

15%

Net Margin is Increasing

13% > 46%

Exceptional Free Cash Flow Margin

18%

Strong 3Y Average Free Cash Flow Margin

22%

Declining Free Cash Flow Margin

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.